| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
In vitro, K134 (K-134) suppresses rat platelet aggregation that is caused by collagen and ADP in a dose-dependent manner. K134 exhibited half-maximal (50%) inhibitory concentration (IC50) values of 2.5 µM and 3.2 µM, in that order. K134 also prevented mice's platelet aggregation in vitro, with dose-dependent IC50 values of 5.5 µM and 6.7 µM for collagen and ADP, respectively [1].
|
|---|---|
| ln Vivo |
In a stroke model, K134 (K-134) significantly delayed middle cerebral artery (MCA) occlusion time at dosages >10 mg/kg and reduced cerebral infarct size at 30 mg/kg (n = 12, 87.5±5.6 vs. 126.8± 7.5 mm3, P<0.01), demonstrating that it has a strong anti-thrombotic action. The total bleeding risk of K134 is typically studied in mice. A single oral dose of 30 mg/kg K134 did not prolong bleeding duration compared with controls (106±5 seconds vs. 110±5 seconds, not significant). Furthermore, sufficiently high plasma concentrations of K134 (13.6 ± 2.3 μM) to suppress platelet aggregation were identified 10 minutes after a single 30 mg/kg dosage in mice, the same time point as in the preceding tests. Bleeding time. Next, the effect of PDE3 inhibitors on thrombosis was also examined in a rat arteriovenous shunt model. K134 can greatly lower the incidence of occlusive shunt thrombosis at dosages higher than 10 mg/kg (half maximum effective dose: ED50=11 mg/kg). At a dosage of 10 mg/kg, the plasma concentration of K134 is 0.43±0.08 µM (Cmax)[1].
|
| References | |
| Additional Infomation |
K-134 has been used in trials studying the treatment of Intermittent Claudication.
|
| Molecular Formula |
C22H29N3O4
|
|---|---|
| Molecular Weight |
399.491
|
| Exact Mass |
399.216
|
| CAS # |
189362-06-9
|
| PubChem CID |
9908900
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.978
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
621
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1CC[C@H]([C@@H](C1)N(C2CC2)C(=O)NCCCOC3=CC4=C(C=C3)NC(=O)C=C4)O
|
| InChi Key |
ULGNGSQNNMKROG-WOJBJXKFSA-N
|
| InChi Code |
InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1
|
| Chemical Name |
1-cyclopropyl-1-[(1R,2R)-2-hydroxycyclohexyl]-3-[3-[(2-oxo-1H-quinolin-6-yl)oxy]propyl]urea
|
| Synonyms |
K134; OPC-33509; K-134
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~125.16 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.26 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5032 mL | 12.5160 mL | 25.0319 mL | |
| 5 mM | 0.5006 mL | 2.5032 mL | 5.0064 mL | |
| 10 mM | 0.2503 mL | 1.2516 mL | 2.5032 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
